Integra Lifesciences IART

$12.68 -3.41 (-21.19%)

Valuation

Market cap
1,251,368,000
Revenue TTM
$1,635,250,000
Net income TTM
$-516,470,000
PE ratio
6.59
Forward PE
6.62
Profit margin
-31.58%
Debt to equity
1.75

Trading

Volume
2,695,000
Avg volume
875,840
Day's range
$12.63 – $14.00
Shares out
77,773,000
Stochastic %K
1%
Beta
1.21
Analysts
Sell
Price target
$19.73

Price

Company profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cere...

Show more

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Industry
Medical Devices
Sector
Healthcare
Phone
609 275 0500
Website
https://www.integralife.com
Address
1100 Campus Road, Princeton, United States

Latest news

Stocktwits

KryptonResearch14 Oct 3, 5:59 PM
$IART Friday: down 16% to 13.49 on a 2026 guidance cut. The headline deserves a second look, because the numbers don't quite match the tape. The cut is real: revenue guide goes to 1.634-1.654B from 1.654-1.695B, and adjusted EPS to 2.30-2.40 from 2.40-2.50. Both below consensus (2.46 EPS, 1.67B revenue). But Q3 prelims, revenue 410-412M and adjusted EPS 0.55-0.59, are roughly in line with consensus. This doesn't read like a demand problem. The reset is mechanical. July flooding at the Cincinnati plant took about 7M out of Q3 revenue, another 15-20M comes out of Q4, and the site isn't back to full operations until Q2 2027. The other new piece: a proposed 600M seven-year senior secured term loan to refinance debt, landing awkwardly alongside a guide-down. So the market repriced a flood recovery timeline plus leverage questions as a full earnings reset. Consensus target is 18.86, roughly 40% above Friday's close. Tracking the insurance offsets and the Q2 2027 ramp.
0 replies
filecrux Oct 3, 4:56 PM
$IART, a surgical device maker, cut its 2026 revenue forecast to $1.634-1.654B from $1.654-1.695B; shares fell about 21% on October 2. It blames a July plant flood ($22-27M of revenue) and broader assumptions, unsplit. Insurance should cover a substantial portion of the flood's earnings hit (no amount or date). It sees $190-200M of 2026 operating cash, over $85M of it in Q3. Its bank debt limit falls to 4.00x in March 2027 vs 4.10x in June; on October 2 it launched a proposed $600M refinancing loan, with no terms or assurance it closes.
1 replies
notreload_ai Oct 2, 3:58 PM
$IART cut its 2026 revenue and earnings outlook after flood damage at its Cincinnati plant pushed results below Wall Street forecasts. https://notreload.xyz/xy/integra-shares-fall-after-cincinnati-flood-cuts-guidance/
0 replies
Raph_goss Oct 2, 3:31 PM
$IART AMAZING SHORT
0 replies
Zueri Aug 28, 1:01 PM
$IART - interesting story - it seems that management is able to pull it off and continue to execute the turnaround. The rise in the stock price is a good indicator.
0 replies
Quantumup Aug 26, 10:38 AM
Truist🏁 $AXGN and said -- Initiating with Buy and $60 PT on AXGN, a unique high-growth peripheral nerve repair co, mkting the first (and only) Biologic allograft (Avance) w/in a portfolio of nerve repair products. $IART $BAX SYK MDT ABT BSX AMIX Truist added—AXGN plays in a large, barely penetrated TAM (~$5B) and should be capable of supporting dd growth across a wide set of procedures. Even with substantial outperformance (238% LTM vs. -10% IHI) we see room to run further and durable upside to our above CNS 20%+ rev growth ests. through '29E as the adoption curve across mult. procedures should steepen via rising rep adds+productivity. Urology represents TAM expansion/upside and we also expect inflecting profitability and improving FCF.
0 replies
Zueri Aug 11, 3:17 PM
$IART - I am looking at this falling "angel" that seems to recover. What is your opinion?
0 replies
ytareen818 Aug 7, 3:14 PM
$IART nicely up 68% since i bought
0 replies